| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.8M | — | +57.5% |
| R&D Expense | $35.0M | — | -11.9% |
| SG&A Expense | $9.7M | — | -9.4% |
| Operating Income | -$33.4M | — | +21.5% |
| Interest Expense | $4.9M | — | +5272.5% |
| Net Income | -$36.8M | — | +10.4% |
| EPS (Basic) | -$0.58 | — |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $66.5M | +16.3% | -54.3% |
| Accounts Receivable | $10.4M | -22.0% | -1.1% |
| Inventory | $9.5M | +20.1% | +0.8% |
| Current Assets | $182.5M | -17.0% | +0.2% |
| Total Assets | $217.9M | -15.2% | -3.0% |
| Current Liabilities |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$35.8M | — | +23.6% |
| Capital Expenditures | $344K | — | -35.0% |
| Investing Cash Flow | $45.3M | — | +357.7% |
| Financing Cash Flow | -$207K | — | +26.6% |
| Free Cash Flow | -$36.2M | — | +23.8% |
| +10.8% |
| EPS (Diluted) | -$0.58 | — | +10.8% |
| $95.9M |
| +122.5% |
| +73.0% |
| Total Liabilities | $196.7M | -2.3% | +35.2% |
| Stockholders' Equity | $21.2M | -61.9% | -73.2% |